Gurgaon-based Ranbaxy Laboratories Ltd has launched a generic version of Prasugrel in India. The product called Prasita is an antiplatelet agent for prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Prasita is solely marketed by Ranbaxy in India.
Following the April 2009 launch of Olvance (olmesartan medoxomil), an antihypertensive originally discovered by Tokyo-based Daiichi Sankyo Company Ltd, Prasita is the second product from the Daiichi Sankyo portfolio to be introduced in India through the Ranbaxy business network. Ranbaxy will create awareness, understanding and acceptance of the new antiplatelet therapy among the target audiences in the country.
On Thursday, Ranbaxy's shares ended 1.34% up at Rs424 on the Bombay Stock Exchange, while the benchmark Sensex closed 1.59% up at 16,922 points.
Inside story of the National Stock Exchange’s amazing success, leading to hubris, regulatory capture and algo scam
Fiercely independent and pro-consumer information on personal finance.
1-year online access to the magazine articles published during the subscription period.
Access is given for all articles published during the week (starting Monday) your subscription starts. For example, if you subscribe on Wednesday, you will have access to articles uploaded from Monday of that week.
This means access to other articles (outside the subscription period) are not included.
Articles outside the subscription period can be bought separately for a small price per article.
Fiercely independent and pro-consumer information on personal finance.
30-day online access to the magazine articles published during the subscription period.
Access is given for all articles published during the week (starting Monday) your subscription starts. For example, if you subscribe on Wednesday, you will have access to articles uploaded from Monday of that week.
This means access to other articles (outside the subscription period) are not included.
Articles outside the subscription period can be bought separately for a small price per article.
Fiercely independent and pro-consumer information on personal finance.
Complete access to Moneylife archives since inception ( till the date of your subscription )
